Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

Quintor is indicated for the treatment of a single infection or mixed infections caused by two or more susceptible organisms. It can also be used for infections caused by organisms resistant to other antibiotics, including aminoglycosides, penicillins and cephalosporins. Because antibacterial concentrations of Quintor are reached in serum and body tissues as well as in the urine after oral administration, Quintor has been suggested for use in treating a wide range of infections caused by susceptible organisms, including infections of the urinary, respiratory and gastrointestinal tracts, gonorrhoea and septicaemia. The extensive tissue penetration of Quintor, combined with its enhanced antibacterial activity (including antipseudomonal activity), allows Quintor to be used alone (pending sensitivity results) or in combination with an aminoglycoside or with beta lactam antibiotics, for instance when severe neutropenia is present, or with an antibiotic active against anaerobes where the presence of Bacteroides fragilis is suspected. Quintor is indicated for the treatment of the following infections caused by sensitive bacteria. Severe systemic infections, such as septicaemia, bacteraemia, peritonitis, infections in immunosuppressed patients with haematological or solid tumours, and in patients in intensive care with specific problems such as infected burns. Respiratory tract infections, including lobar and bronchopneumonia, acute and chronic bronchitis, acute exacerbation of cystic fibrosis, bronchiectasis and empyema. Urinary tract infections, including uncomplicated and complicated urethritis, cystitis, pyelonephritis, prostatitis and epididymitis. Skin and soft tissue infections, such as infected ulcers, wound infections, abscesses, cellulitis, otitis externa, erysipelas and infected burns. Gastrointestinal infections, such as enteric fever and infective diarrhoea. Infections of the biliary tract, such as cholangitis, cholecystitis and empyema of the gall bladder. Intra abdominal infections, such as peritonitis and intra abdominal abscesses. Bone and joint infections, including osteomyelitis and septic arthritis. Pelvic infections, such as salpingitis, endometritis and pelvic inflammatory disease. Eye, ear, nose and throat infections, such as otitis media, sinusitis, mastoiditis and tonsillitis. And gonorrhoea, including urethral, rectal and pharyngeal gonorrhoea caused by beta-lactamase producing organisms or organisms moderately sensitive to penicillin.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Ciprofloxacin is a synthetic quinolone anti-infective agent with a broad spectrum of activity. It is active against most gram negative aerobic bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa. It is also active against gram positive aerobic bacteria, including penicillinase producing, non penicillinase producing, and methicillin resistant staphylococci, although many strains of streptococci are relatively resistant to the drug. Its bactericidal action results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA. Following oral administration, it is rapidly and well absorbed from the GI tract and is widely distributed into body tissues and fluids. Its half life is about 3.5 hours. About 30% to 50% of an oral dose is excreted in the urine within 24 hours as unchanged drug and biologically active metabolites.

Pregnancy & Breastfeeding

Reproduction studies performed in mice, rats and rabbits using parenteral and oral administration did not reveal any evidence of teratogenicity, impairment of fertility or impairment of peri/post natal development. However as with other quinolones, Ciprofloxacin has been shown to cause arthropathy in immature animals and therefore its use during pregnancy is not recommended. Studies in rats have indicated that Ciprofloxacin is secreted in milk, administration to nursing mothers is thus not recommended.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Dosage: General dosage recommendations: The dosage of Ciprofloxacin is determined by the severity and type of infection, the sensitivity of the causative organism(s), and the age, weight and renal function of the patient. Adults: The dosage range for adults is 100 to 750 mg twice daily. In infections of the lower and upper urinary tract (depending on severity): 250 to 500 mg twice daily. In respiratory tract infections: 250 to 500 mg twice daily for both upper and lower respiratory tract infections, depending on the severity. For the treatment of known Streptococcus pneumoniae infection, the recommended dosage is 750 mg twice daily. In gonorrhea: a single dose of 250 or 500 mg. In the majority of other infections: 500 to 750 mg twice daily should be administered. Cystic fibrosis: in adults with pseudomonal infections of the lower respiratory tract, the normal dose is 750 mg twice daily. As the pharmacokinetics of Ciprofloxacin remain unchanged in patients with cystic fibrosis, the low body weight of these patients should be taken into consideration when determining dosage. Impaired renal function: dosage adjustment is not usually required except in patients with severe renal impairment (serum creatinine greater than 265 micromol/l or creatinine clearance less than 20 ml/minute). If adjustment is necessary, this may be achieved by reducing the total daily dose by half, although monitoring of drug serum levels provides the most reliable basis for dose adjustment. Elderly: although higher Ciprofloxacin serum levels are found in the elderly, no adjustment of dosage is necessary. Adeloscents and children: as with other drugs in its class, Ciprofloxacin has been shown to cause arthropathy in weight bearing joints of immature animals. Although the relevance of this to man is unknown, its use in children, growing children and growing adolescents is not recommended. However, where the benefit of using Ciprofloxacin is considered to outweigh the potential risk, the dosage should be 7.5 to 15 mg/kg/day depending upon the severity of infection, administered in two divided doses. Duration of treatment: the duration of treatment depends upon the severity of infection, clinical response and bacteriological findings. For acute infections: the usual treatment period is 5 to 10 days with Ciprofloxacin tablets. Generally treatment should be continued for three days after the signs and symptoms of the infection have disappeared. Extended release tablet: in uncomplicated urinary tract infection (acute cystitis), the recommended dose of extended release tablet is one 1000 mg tablet once daily for three days. For IV infusion, urinary tract infection: mild to moderate, 200 mg every 12 hours for 7 to 14 days; severe or complicated, 400 mg every 12 hours for 7 to 14 days. Lower respiratory tract infection: mild to moderate, 400 mg every 12 hours for 7 to 14 days; severe or complicated, 400 mg every 8 hours for 7 to 14 days. Nosocomial pneumonia: mild, moderate or severe, 400 mg every 8 hours for 10 to 14 days. Skin and skin structure: mild to moderate, 400 mg every 12 hours for 7 to 14 days; severe or complicated, 400 mg every 8 hours for 7 to 14 days. Bone and joint infection: mild to moderate, 400 mg every 12 hours for more than 4 to 6 weeks; severe or complicated, 400 mg every 8 hours for more than 4 to 6 weeks. Intraabdominal (acute abdomen): complicated, 400 mg every 12 hours for 7 to 14 days. Acute sinusitis: mild or moderate, 400 mg every 12 hours for 10 days. Chronic bacterial prostatitis: mild or moderate, 400 mg every 12 hours for 28 days.

Side Effects & Interactions